학술논문

Targeting senescent cells alleviates obesity‐induced metabolic dysfunction
Document Type
article
Source
Aging Cell. 18(3)
Subject
Medical Physiology
Biomedical and Clinical Sciences
Nutrition
Obesity
Prevention
Diabetes
2.1 Biological and endogenous factors
Aetiology
Cardiovascular
Metabolic and endocrine
Adipocytes
Adipogenesis
Adipose Tissue
Aging
Animals
Cell Death
Cell Line
Cellular Senescence
Cyclin-Dependent Kinase Inhibitor p16
Dasatinib
Female
Ganciclovir
Glucose
Humans
Inflammation
Insulin Resistance
Macrophages
Male
Mice
Mice
Inbred C57BL
Mice
Transgenic
Quercetin
adipogenesis
aging
cellular senescence
dasatinib
quercetin
senolytics
type 2 diabetes
Biological Sciences
Medical and Health Sciences
Developmental Biology
Biological sciences
Biomedical and clinical sciences
Language
Abstract
Adipose tissue inflammation and dysfunction are associated with obesity-related insulin resistance and diabetes, but mechanisms underlying this relationship are unclear. Although senescent cells accumulate in adipose tissue of obese humans and rodents, a direct pathogenic role for these cells in the development of diabetes remains to be demonstrated. Here, we show that reducing senescent cell burden in obese mice, either by activating drug-inducible "suicide" genes driven by the p16Ink4a promoter or by treatment with senolytic agents, alleviates metabolic and adipose tissue dysfunction. These senolytic interventions improved glucose tolerance, enhanced insulin sensitivity, lowered circulating inflammatory mediators, and promoted adipogenesis in obese mice. Elimination of senescent cells also prevented the migration of transplanted monocytes into intra-abdominal adipose tissue and reduced the number of macrophages in this tissue. In addition, microalbuminuria, renal podocyte function, and cardiac diastolic function improved with senolytic therapy. Our results implicate cellular senescence as a causal factor in obesity-related inflammation and metabolic derangements and show that emerging senolytic agents hold promise for treating obesity-related metabolic dysfunction and its complications.